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Objective: To characterize the prevalence and impact of symptoms of scleroderma in Brazil-
ian patients and to describe their satisfaction with medical care and psychological symp-
toms.
Methods: One-hundred and twenty eight Brazilian scleroderma patients participated in an 
online survey by fi lling out a Portuguese version of the Canadian Scleroderma Patient Sur-
vey of Health Concerns and Research Priorities. The mean age of participants was 38 years 
old (SD = 12.33), and most of the participants were females (n = 108, 88%).
Results: Hardening/tightening of skin, itchy skin and joint pain were symptoms reported 
as being most frequent, whereas muscle pain and diffi culty climbing stairs were symp-
toms reported as having a higher impact. Participants reported dissatisfaction regarding 
the medical care. Psychological evaluations suggested that participants who scored above 
clinical values for depression was signifi cantly high (90%; n = 77). In addition, 48% (n = 42) 
of participants fi t the clinical criteria for anxiety disorder, and 40% (n = 35) of participants 
fi t the clinical criteria of social phobia. Finally, body image disturbance was reported by 69% 
(n = 88) of participants. 
Conclusions: The physical and psychological symptoms associated with scleroderma have 
a signifi cant impact on patient quality of life. The Brazilian patients in the current sample 
report higher levels of dissatisfaction with medical care than patients from Canada and Eu-
ropean countries. These Brazilian patients also report more psychopathology, particularly 
symptoms of depression. The current results suggest that there is a need for professionals 
to consider and attend to the individual problems of scleroderma patients.
© 2013 Elsevier Editora Ltda. All rights reserved.
Sintomas de doença e adaptação psicológica em pacientes brasileiros 
com esclerodermia
Palavras-chave:
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Esclerodermia
Sintomas psicológicos
r e s u m o
Objetivo: Caracterizar a prevalência e o impacto dos sintomas de esclerodermia em pa-
cientes brasileiros e descrever sua satisfação com o atendimento médico e sintomas psi-
cológicos.
Métodos: Cento e vinte e oito pacientes brasileiros com esclerodermia participaram em uma 
pesquisa online preenchendo a versão portuguesa do Canadian Scleroderma Patient Sur-
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vey of Health Concerns and Research Priorities. A média de idade dos participantes foi 38 
anos (DP = 12,33) e a maioria dos participantes era constituída por mulheres (n = 108, 88%).
Resultados: Endurecimento/retesamento da pele, coceira na pele e dor articular foram sin-
tomas informados como mais freqüentes, enquanto que dor muscular e difi culdade para 
subir escadas foram sintomas informados como tendo maior impacto. Os participantes 
informaram insatisfação em relação ao atendimento médico. As avaliações psicológicas 
sugeriram que o percentual de participantes com pontuação acima dos valores clínicos 
para depressão foi signifi cativamente elevado (90%; n = 77). Além disso, 48% (n = 42) dos 
participantes se enquadravam nos critérios clínicos para transtorno da ansiedade e 40% (n 
= 35) dos participantes se enquadravam nos critérios clínicos de fobia social. Finalmente, 
69% (n = 88) dos participantes informaram transtornos da imagem corporal. 
Conclusões: Os sintomas físicos e psicológicos associados com esclerodermia têm impacto 
signifi cativo na qualidade de vida dos pacientes. Na presente amostra, os pacientes brasi-
leiros informam níveis mais altos de insatisfação com o atendimento médico, em compa-
ração com pacientes do Canadá e de países europeus. Esses pacientes brasileiros também 
informam mais casos de psicopatologia, particularmente sintomas de depressão. Nossos 
resultados sugerem que há necessidade que os profi ssionais levem em consideração os 
problemas individuais dos pacientes com esclerodermia e cuidem desses problemas. 
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Scleroderma, or systemic sclerosis, is a connective tissue dis-
ease that causes vascular, infl ammatory and fi brotic dysfunc-
tion of organ systems.1 The etiology of this chronic disease 
remains unknown. The characteristics of scleroderma include 
microvascular damage, excessive deposition of collagen in 
the skin and organs, Raynaud phenomenon and hardening of 
the skin.2 Scleroderma can damage the functioning of respira-
tory, gastrointestinal, and cardiac system, in addition to dam-
aging renal function. Consequently, scleroderma is highly 
morbid and is associated with high rates of mortality.1 Other 
scleroderma symptoms include musculoskeletal disorders 
such as joint pain, arthritis, fl exion contractures of the joints 
and muscle weakness.3 Because scleroderma is a rare disease 
with multiple symptoms, it may be diffi cult to diagnose and 
to make an accurate prognosis from the symptoms.4
Rheumatic diseases involve visible physical changes that 
correlate with the progression of the disease; however, sclero-
derma involves physical changes that are even more visible5 
and that tend to worsen over time.6 In most cases, these phys-
ical disfi gurements tend to localize in the face and hands. At 
the initial stages of the disease, physical changes include: 
swelling of fi ngers, loss of natural skin wrinkles, brightening 
of skin tone, hypo- or hyper-pigmentation, and facial changes, 
which include change in appearance of the eyes and nose, loss 
of fl exibility in the lips, loss of ability to fully open the mouth, 
and diffi culty in completely closing the lips.5 Dissatisfaction 
with body image is more prevalent in younger patients with 
severe symptoms and is associated with age and disability.7 
The results from a Canadian study suggest that over three 
quarters of patients reported concerns about body image due 
to scleroderma.6
Regarding depressive symptoms, the same Canadian study 
found that approximately half of the participants reported 
feeling “down, depressed or hopeless” for at least several days 
during the previous two weeks. It is noteworthy that depres-
sive symptoms are very common in patients with scleroderma8 
and clinical results are negatively infl uenced by the presence 
of depressive symptoms. Studies show that female patients re-
port being dissatisfi ed with their body image and depression 
appears to be moderating this relation.7 Anxiety symptoms are 
also very frequent in patients with scleroderma.9
Moreover, scleroderma patients have high physical and 
psychological morbidity and there are costs associated with 
regular use of healthcare with long periods of morbidity.10 
The “Canadian Scleroderma Patient Survey of Health Con-
cerns and Research Priorities” suggests that patients with 
scleroderma are more dissatisfi ed with healthcare than other 
chronically ill patients.6
However, until now, the frequency and impact of sclero-
derma symptoms and the psychological symptoms exhibited 
by scleroderma patients were studied only in Canada and 
Europe. This study intends to extend on this research by in-
vestigating the psychosocial impact on scleroderma patients 
living under different geographical and cultural conditions. 
Specifi cally, this study focuses on scleroderma patients living 
in Brazil, a country in which climatic and cultural characteris-
tics differ signifi cantly from European countries and Canada. 
For instance, evidence suggests that cold weather exacerbates 
scleroderma symptoms by causing Raynaud’s phenomenon 
and pain in joints and muscles. However, it is unclear how 
patients in Brazil, where the climate is warm, fare relative to 
patients living in Canada and European countries.
Another relevant cultural difference between these coun-
tries is related to body image. Specifi cally, Brazilian patients 
may be more preoccupied with their body image because, due 
to the hot climate, their bodies are more exposed throughout 
the year. Moreover, body image is generally important in Bra-
zil, and because the illness affects mainly women, we expect 
higher rates of dissatisfaction with body image in the Brazil-
ian sample. Finally, because scleroderma is a rare disease, it 
can be related to specifi c diffi culties in fi nding appropriate 
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care, which may decrease patients’ satisfaction with medical 
services and affect their global well-being. Thus, the current 
study aimed to explore rates of satisfaction with medical care 
amongst patients with scleroderma.
In light of the issues mentioned above, the objectives of 
the current study were as follows: (1) to characterize the main 
symptoms of scleroderma and their impact on scleroderma 
patients from Brazil; (2) to assess who made the diagnoses 
and how patients evaluated their satisfaction with medical 
care in terms of general satisfaction, technical quality, inter-
personal manner, communication, fi nancial costs, time spent 
with doctor, accessibility and convenience; (3) to describe the 
psychological symptoms, including depressive, anxiety and so-
cial phobia symptoms; (4) to assess the impact of physical ap-
pearance on social functioning; and (5) to evaluate predictors 
of depression, anxiety, social phobia and body image in Brazil-
ian patients with scleroderma, controlling for education level, 
a variable that is known to infl uence psychological adjustment.
Patients and methods
Participants
The sample consisted of 128 Brazilian scleroderma patients. 
The mean age of the participants was 38 years old (SD = 12.33), 
and the majority of the sample was female (n = 108, 88%) and 
white (n = 99, 81%). The majority of participants were mar-
ried or living as married (n = 71, 60%). Only two participants 
lived alone. Twenty-seven percent (n = 31) of the sample were 
working full-time. Thirty-nine percent (n = 24) of participants 
had a college degree, 16% (n = 10) completed high school and 
26% (n = 16) had the fi rst level of education
The majority of participants reported being diagnosed 
with diffuse scleroderma (n = 51, 46%) or limited scleroderma 
(n = 18, 16%). 
Instruments
Canadian Scleroderma Patient Survey of Health Concerns and Re-
search Priorities.11 The questionnaire was distributed to us by 
the original authors, and we received proper authorization to 
translate the questionnaire. The questionnaire was translat-
ed, back-translated and validated into European Portuguese. 
This questionnaire evaluates the most important aspects of 
living with scleroderma and includes the following 11 sec-
tions: demographics, diagnosis and disease, healthcare ser-
vices utilization, healthcare services reimbursement, health-
care services reimbursement needs, type of medical care, 
symptoms, employment, sensations, physical appearance, 
and commentaries. For the purpose of the current study, only 
a subset of these sections was analyzed. The sections are de-
scribed in Table 1.
Procedure
We contacted the Brazilian Association of Patients with Sys-
temic Sclerosis (ABRAPES), who divulgated the study to their 
associates. Patients were invited to complete the survey on-
line, using Survey Monkey.
Confi dentiality and anonymity were guaranteed. Partici-
pants did not provide any personal information, including 
name, date of birth, or telephone number. Data were collected 
between December 2010 and July 2011.
Statistical analysis
The data analysis was performed using the statistical soft-
ware package SPSS 18 (for Windows). We ran an exploratory 
data analysis to verify the normality and homogeneity of the 
variables’ distribution, however, this was not verifi ed in our 
sample. Thus, we conducted parametric and non-parametric 
tests, and found that the results were equivalent. Finally, we 
choose to report the results of the parametric tests because 
these were more robust.12
We used descriptive statistics to describe the data and 
inferential statistics to test relations among the variables. 
We ran a multiple regression analysis to assess predictors 
of depression, anxiety, social phobia and body image. In this 
model, variables that showed signifi cant correlations with the 
Table 1 – Sections and aims/content of each section 
of the Canadian Scleroderma Patient Survey of Health 
Concerns and Research Priorities (Taillefer SS, Bernstein 
J, Schieir O, Buzza R, Hudson M, Scleroderma Society of 
Canada, et al. Canadian Scleroderma Survey of Health 
Concerns and Research Priorities. 2010. Portuguese 
version, Leite C, Maia A, 2011. Escola de Psicologia, 
Universidade do Minho) as was used in the study.
Sections Aims /content
Diagnosis and 
disease
To describe the medical status of participants
Medical care To assess how scleroderma patients feel about 
the medical care provided to them
Satisfaction with 
medical care
This part is organized according to 
the following seven domains: general 
satisfaction, technical quality of care, 
interpersonal manner, communication, 
fi nancial aspects, time spent with physician, 
and accessibility and convenience of 
care. Response options ranged from 1 
(strongly agree) to 5 (strongly disagree) and 
items were scored so that higher scores 
refl ected satisfaction with medical care. 
This section uses an existing survey: The 
Patient Satisfaction Questionnaire (Marshall 
GN, Hays RD. The patient satisfaction 
questionnaire short-form (PSQ-18). Santa 
Monica, CA: Rand Corporation; 1994). 
Symptoms The questions are based on The Scleroderma 
Assessment Questionnaire (SAQ) (Ostojic 
PS, Damjanov NS. The scleroderma 
assessment questionnaire (SAQ). Z Reumatol. 
2006;65:168-75) and several articles, with 
the aim to list the frequency and impact 
of 69 symptoms. The response options for 
“symptom frequency” are as follows: never, 
rarely, sometimes, most of the time, and 
always. The response options for “symptom 
impact” are as follows: no impact, minimal, 
moderate, severe, and extremely severe
Employment Patients’ employment
(continued on next page)
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predicted variables were entered as predictors. In all of our 
analyses, we set the level of signifi cance at P < 0.05 and the 
level of marginal signifi cance at P < 0.1. 
Results
The frequency and impact of symptoms are summarized in 
Table 2. Regarding the frequency of symptoms, the fi ve most 
common symptoms reported by patients were the following: 
joint pain (96%), hardening/tightening of skin (90%), heartburn 
(89%), diffi culty concentrating (88%) and diffi culty remember-
ing things (88%). The fi ve symptoms with the greatest impact 
were the following: muscle pain (91%), joint pain (84%), Rayn-
aud’s (84%), fatigue (83%) and diffi culty sleeping (82%). 
Some participants did not answer items related to how 
frequently they experienced symptoms, however, all partici-
pants responded to items probing the impact of these symp-
toms.
Most participants reported being diagnosed with sclero-
derma by a rheumatologist (n = 70, 65%). Only 17% (n = 18) 
of participants received their diagnosis from the fi rst doctor 
they consulted. Finally, 27% (n = 29) of participants consulted 
more than 5 physicians before receiving their diagnosis.
Table 1 – Sections and aims/content of each section 
of the Canadian Scleroderma Patient Survey of Health 
Concerns and Research Priorities (Taillefer SS, Bernstein 
J, Schieir O, Buzza R, Hudson M, Scleroderma Society of 
Canada, et al. Canadian Scleroderma Survey of Health 
Concerns and Research Priorities. 2010. Portuguese 
version, Leite C, Maia A, 2011. Escola de Psicologia, 
Universidade do Minho) as was used in the study. 
(continued).
Sections Aims /content
Sensations Aims to evaluate levels of depression, 
anxiety and social phobia. Depression was 
assessed with the instrument Patient Health 
Questionnaire (PHQ-2) (Kroenke K, Spitzer 
RL. The PHQ-9, a new depression diagnostic 
and severity measure. Psychiatric Annals. 
2002;32:1-7). The cut-off of this two-item 
instrument is three, higher than or equal to 
three means sensitivity to severe depression. 
The fi rst item assesses anhedonia and 
the second item assesses dysphoria. The 
sum of the two items is a maximum of six. 
Anxiety was assessed with the instrument 
Generalized Anxiety Disorder (GAD) (Kroenke 
K, Spitzer RL, Williems JBW, Monahan PO, 
Lowe B. Anxiety disorders in primary care: 
prevalence, impairment, comorbidity, and 
detection. Annals of Internal Medicine. 
2007;146:317-25). Includes two items and 
the cut-off of this two-item instrument is 
three, higher than or equal to three means 
generalized anxiety disorder. The sum of the 
two items is a maximum of six. Finally, social 
phobia was evaluated with the instrument 
Mini SPIN (Social Phobia Inventory) (Connor 
KM, Kobak KA, Churchill LE, Katzelnick D, 
Davidson JRT. Mini-SPIN: a brief screening 
assessment for generalized social 
anxiety disorder. Depression and Anxiety. 
2001;14:137-40). The cut-off of the items of 
this instrument is six. Higher than or equal 
to six means general social anxiety disorder. 
The sum of items varies between 0 and a 
maximum of 12.
Physical 
appearance
To assess concerns about body image. The 
three questions used in this section were 
taken from the instrument The Body Image 
Disturbance Questionnaire (Cash TF, Phillips 
KA, Santos MT, Hrabosky JI. Measuring 
“negative body image”: validation of the 
body image disturbance questionnaire 
in a nonclinical population. Body Image. 
2004;1:363-72).
Table 2 – Frequency and Impact (reported moderate or 
extremely severe) of the most reported symptoms in 
Brazilian scleroderma patients.
Frequency n ( %) Impact n ( %)
Hardening/tightening of 
skin
88 (90%) 97 (76%)
Itchy skin 82 (87%) 92 (72%)
Joint pain 92 (96%) 108 (84%)
Muscle pain 83 (87%) 116 (91%)
Heartburn 89 (89%) 102 (80%)
Diarrhea 81 (84%) 88 (67%)
Fatigue 83 (86%) 106 (83%)
Diffi culty sleeping 83 (80%) 105 (82%)
Diffi culty concentrating 85 (88%) 93 (73%)
Diffi culty remembering 
things
82 (88%) 100 (78%)
Raynaud’s 84 (86%) 108 (84%)
Changes in skin color 81 (81%) 88 (69%)
Swollen joints 79 (81%) 104 (81%)
Numbness in feet or lower 
legs
78 (81%) 104 (81%)
Carpal tunnel syndrome 79 (81%) 106 (83%)
Migraine headaches 76 (79%) 96 (75%)
Diffi culty climbing stairs 74 (76%) 110 (86%)
Stiffness in the hands 72 (76%) 109 (85%)
Medication side effects 73 (75%) 105 (82%)
Skin pain 72 (75%) 109 (85%)
Diffi culty swallowing 73 (75%) 94 (73%)
Diffi culty walking 70 (74%) 107 (84%)
Shortness of breath 70 (74%) 104 (81%)
Chest pain 73 (74%) 96 (75%)
Vaginal dryness 54 (74%) 101 (79%)
Dry mouth 71 (73%) 94 (73%)
Hypersensitivity to the 
sun
70 (73%) 102 (80%)
Bad taste in the mouth at 
night
72 (73%) 95 (74%)
Diffi culty turning on a 
faucet
69 (73%) 104 (81%)
Nausea 69 (72%) 95 (74%)
Diffi culty dressing 68 (71%) 101 (79%)
Diffi culty getting in/out 
of a car
69 (70%) 103 (81%)
Diffi culty holding objects 68 (70%) 102 (80%)
Dry eyes 67 (70%) 109 (85%)
Diffi culty self-washing 66 (70%) 97 (76%)
Diffi culty opening the 
mouth
66 (68%) 105 (82%)
Diffi culty fully opening 
the hand
64 (66%) 97 (76%)
409R E V  B R A S  R E U M A T O L .  2 0 1 3 ; 5 3 ( 5 ) : 4 0 5 – 4 1 1
The results taken from the section “health care satisfac-
tion” are summarized in Table 3. In general, participants re-
ported negative evaluations regarding the medical care pro-
vided to them. The area where they were the least satisfi ed 
related to the fi nancial costs of the disease.
The majority of participants (69%, n = 75) reported that 
scleroderma affected their ability to work. In addition, 90% (n 
= 77) of participants scored above the clinical criteria for de-
pression, whereas 48% (n = 42) and 40% (n = 35) of participants 
scored above the clinical criteria for anxiety and social pho-
bia, respectively. Body image disturbance was reported by 69% 
(n = 88) of participants, with 50% of these participants report-
ing that they were “very” or “extremely” concerned about the 
appearance of some parts of the body, which they considered 
to be especially unattractive due to scleroderma.
Correlation between age, education level, years since diag-
nosis, frequency and impact of symptoms, psychosocial vari-
ables and education level are presented in Table 4. As shown, 
there is a signifi cant correlation between frequency and im-
pact of symptoms and among the psychological variables. 
Education level of the participants is not correlated with oth-
ers variables.
The multiple regression model that was used to test pre-
dictors of depression explained 18% of the variance related 
to depression symptoms (R2aj = 0.11, P < 0.05; F(6,69) = 2.57, P 
< 0.05). The “impact of symptoms” (t = 0.31, P < 0.05) variable 
was the only signifi cant predictor in this model (Table 5). Re-
garding anxiety, the current model explained 22% of variance 
in anxiety symptoms (R2aj = 0.16, P < 0.01; F(5,70) = 3.85, P < 
0.01). The “frequency of symptoms” (t = -2.53, P < 0.05) and 
“body image” (t = 1.82, P < 0.1) variables were the two signifi -
cant predictors in this model. Regarding social phobia symp-
toms, the current model explained 34% of variance related to 
social phobia (R2aj = 0.28, P < 0.001) (F(6,69) = 5.96, P < 0.001), 
where the “body image” (t = 4.45, P < 0.001) variable was the 
only signifi cant predictor of social phobia. Finally, regarding 
body image, the current model explained 28% of the variance 
related to body image (R2aj = 0.23, P < 0.001) (F(4,65) = 6.19, P < 
0.001). In this model, “years of diagnosis” (t = 1.82, P < 0.1) and 
“social phobia” (t = 3.76, P < 0.001) were the two signifi cant 
predictors of “body image” variability.
Discussion
In the present study we intended to assess the most frequent 
symptoms experienced by Brazilian scleroderma patients and 
the impact of these symptoms on patients’ everyday life. In 
addition, we aimed to assess participants’ level of satisfaction 
with their medical care and to assess participants’ levels of 
depression, anxiety, social phobia and body image. Finally, we 
intended to evaluate predictors of depression, anxiety, social 
phobia and body image.
Regarding the frequency of symptoms, our results were 
similar to fi ndings found in a Canadian sample and European 
samples.6,13 Interestingly, while evidence suggest that Rayn-
aud’s phenomenon is exacerbated by cold weather, we found 
similar levels of prevalence of this symptom in Brazil (i.e., 86% 
of patients compared to 94% in a Canadian sample and 90% 
in a European sample6,13). It is worth noting that stress may 
worsen Raynaud’s phenomenon, and there are other factors 
that may contribute to the current pattern of results. Relat-
edly, symptoms such as joint pain also tend to worsen in cold 
weather, however, this symptom was highly prevalent in our 
sample from Brazil 96% (compared to 94% in Canada and Eu-
rope6,13). As mentioned, this pattern of results may be due to 
other factors, including depression, whose contribution to the 
disease or the report of symptoms need to be better explored 
in future studies.
Scleroderma remains unknown to many health profes-
sionals and the symptoms tend to be confounded with symp-
toms of other diseases for a long time. This could explain why 
only 17% of patients were diagnosed with scleroderma by the 
fi rst doctor they consulted. Relatedly, satisfaction with medi-
cal care of patients in Brazil is low and is considerably lower 
than levels of satisfaction reported by Canadian and European 
patients. For instance, on a 1 to 5 scale, which indicates “low” 
to “high satisfaction”, respectively, Brazilian patients rated “fi -
nancial aspects” at 1.93, while the European and Canadian pa-
tients rated this item at 3.2. These results were corroborated 
when we compared reported satisfaction with medical care 
in Canada, Europe and Brazil, founding that levels of satisfac-
tion were higher in both Canada and Europe relative to Brazil. 
Such differences in satisfaction with medical care may arise 
from the distinct economic conditions of the populations, or 
from the organization and /or availability of access to the Na-
tional Health Service in Brazil.
Finally, our results show that 90% of participants reported 
symptoms that are above the cut-off for depression, a fi nding 
that supports the previous evidence that depression is com-
mon amongst patients with scleroderma.8 These results are 
far more robust when compared to data found in the Canadi-
an study, in which 48%6 of patients fi t a diagnosis for depres-
sion, a difference that raises serious concerns. In the current 
sample, depression was associated with the variables of age, 
symptom “frequency” and “impact”, anxiety and social pho-
bia, suggesting that the disease is affecting more the older 
and the ones that have more symptoms. In this sample, the 
symptom “impact” was the main predictor, showing the costs 
in terms of mental health of the limitations in everyday life 
associated with symptoms.
Regarding anxiety symptoms, the results indicate that 
approximately half of participants (48%) reported symptoms 
of anxiety. This result is consistent with the idea that anxi-
ety is very prevalent in people with some type of physical 
disfi gurement14 and that anxiety is common in scleroderma 
patients.9 In the current sample, anxiety was associated with 
age, frequency of symptoms, body image, depression and so-
Table 3 – Satisfaction with medical care in Brazilian 
scleroderma patients.
Mean (SD)
General satisfaction 2.24 (1.49)
Technical quality of care 2.30 (1.40)
Interpersonal manner 2.59 (1.70)
Communication 2.40 (1.58)
Financial aspects 1.93 (1.41)
Time spent with physician 2.29 (1.56)
Accessibility and convenience 2.17 (1.45)
410 R E V  B R A S  R E U M A T O L .  2 0 1 3 ; 5 3 ( 5 ) : 4 0 5 – 4 1 1
cial phobia. The regression analysis showed that “frequency 
of symptoms” and “body image” were the most signifi cant 
predictors of anxiety. Because scleroderma is characterized 
by a complex set of symptoms (including the ones that con-
tribute to the change in body image), the management of 
them is a target that should be considered in order to reduce 
anxiety.
Regarding social phobia, 40% of participants reported this 
problem. Only part of scleroderma patients have face disfi gu-
ration, but changes in hands and other visible parts can be 
a challenge to the ones that are affected. Previous literature 
suggests that people with disfi gurement tend to avoid social 
situations,14 and the “body image” variable was the main pre-
dictor of social phobia in our sample, a result that can be un-
derstood in the dynamics between negative body image and 
avoidance of social situations.
Finally, regarding body image disturbance, 69% of partici-
pants reported such a disturbance in our sample. This fi nding 
complements the fact that scleroderma involves many physi-
cal changes on visible parts of the body.14 However, the results 
in our sample are signifi cantly higher than those found in a 
Canadian sample (23%).6 This difference may be due to par-
ticular weather conditions in Brazil that require more bodily 
exposure throughout most of the year, and the consequent 
diffi culty to disguise physical disfi gurements.
Conclusions
The current study offers a number of challenging results, 
including support for a serious impact of scleroderma on the 
daily functioning of Brazilian patients, and a very high per-
centage of psychological suffering amongst these patients. 
The total population in Brazil is over 194 million people and 
scleroderma affects approximately 44 in every 100,000 peo-
ple.15 These statistics suggest that 83,600 people in Brazil may 
suffer from scleroderma. In light of this estimate, one main 
limitation of the study is the relatively small number of par-
ticipants used in the sample.
A second major limitation of the study is the method by 
which participants were recruited. Specifi cally, data collec-
tion was performed through the collaboration of a patient`s 
association (ABRAPES) and thus this study only included 
patients who were somehow connected to this associa-
tion. These participants may have characteristics that are 
not representative of Brazilian scleroderma patients in the 
general population. Furthermore, the fact that the question-
naire had to be fi lled out online may have signifi cantly lim-
ited the range of our sample. Still, it is noteworthy that even 
if our sample refl ects a part of the population with higher 
socio-economic status and higher social functioning, their 
reported satisfaction with medical care is still lower than 
that in patients from other countries and that psychologi-
cal symptoms still had a negative impact on the majority 
Table 4 – Pearson correlations among disease variables and psychosocial variables in Brazilian scleroderma patients.
Variable 1 2 3 4 5 6 7 8
1. Age
2. Years since diagnosis 0.17a
3. Frequency of symptoms -0.15a 0.02
4. Impact of symptoms -0.16a 0.02 0.95d
5. Body image 0.10 0.23b -0.04 -0.09
6. Depression 0.22a 0.17 -0.19a -0.20a 0.42d
7. Anxiety 0.24b 0.12 -0.27b -0.27* 0.31c 0.63d
8. Social phobia 0.25b 0.10 -0.28c -0.32c 0.47d 0.35c 0.22b
9. Level of education -0.18 -0.10 -0.02 -0.04 -0.07 -0.18 0.08 -0.15
aP < 0.1.
bP < 0.05.
cP < 0.01.
dP < 0.001
Table 5 – Results of multiple regression analysis to test 
predictors of depression, anxiety, social phobia and 
body image in Brazilian scleroderma patients.
Depression R2(R2aj) = 0,18 (0,11); F(6,69) = 2.57b
ȕ t
Age 0.11 0.96
Frequency of symptoms 0.1 0.78
Impact of symptoms 0.31 2.55b
Body image 0.11 0.84
Anxiety 0.14 1.15
Social phobia 0.02 0.12
Anxiety: R2(R2aj) = 0,22(0,16); F(5,70) = 3.85c
Age 0.16 1.45
Frequency of symptoms -0.28 -2,.53b
Body image 0.23 1.82a
Depression 0.13 1.15
Social phobia -0.05 -0.39
Social phobia: R2(R2aj) = 0,34(0,28); F(6,69) = 5.96d
Age 0.14 1.32
Frequency of symptoms -0.13 -1.19
Impact of symptoms 0.15 1.34
Body image 0.46 4.45d
Depression 0.01 0.12
Anxiety -0.04 -0.35
Body image: R2(R2aj) = 0,28(0,23);F(6,69) = 6.19d
Years of diagnosis 0.2 1.82a
Social phobia 0.41 3.76d
aP < 0.1.
bP < 0.05.
cP < 0.01.
dP < 0.001
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of the Brazilian patients. Thus, as a whole, the current data 
suggest that it is necessary that health professionals are bet-
ter equipped to address patients with scleroderma and that 
specialized support is provided to these patients. We hope 
that the current study may motivate further research on 
scleroderma patients in Brazil, calling attention to the areas 
of concern highlighted by our data.
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